Interestingly, the difference in both of our findings may be partially attributed to the TNM stage proportion of the samples.
A previously published score (CAPRA) (Cooperberg et al, 2005) based on Gleason score, PSA, clinical stage, proportion of positive cores, and age was computed for each patient.
This was expected as the UMVUE is obtained as the conditional expectation of the first stage proportion given (M,S), without using any information on the decision boundaries at the second stage.
For dichotomous data outcomes (proportion of participants with gametocytes or asexual stages, proportion of participants infectious to mosquitoes, and proportion of mosquitoes infected), we extracted the number of participants experiencing the event of interest and the total number of patients or mosquitoes in each treatment arm of each trial.
In univariate analysis, nodal metastasis was associated with the presence of any LVSI (95.9% vs. 56.7%, P < 0.001), tumor stage (proportion of LVSI presenting tumor, T1 vs. T2 vs. T3: 23.1% vs. 50% vs. 90.2%, P < 0.001), and high-grade serous carcinoma (86.0% vs. 61.8%, P = 0.004) (Table 2, Fig. 1A C).
The changes of pathological stage proportions have an impact on overall PSA recurrence-free survival.
A greater proportion of pT4 tumours were seen in the interval cancer group (37.5% vs 22.5%), although this and the overall T-stage proportions were not significantly different between groups.
There was a slight improvement in stage: the proportion of stage I II was 2.8% in the 1976 1980 period and 8.8% in the 2001 2005 period (P<0.001).
Among women with TNM stage, the proportion with stage I disease was 30.1% in Denmark, compared with 42 45% in other countries.
As previously reported (Lyratzopoulos et al, 2013a), among women with known stage, the proportion diagnosed in earlier stage progressively decreases with age over 70 years.
